Department of Urology and Andrology, Paracelsus Medical University Salzburg, Salzburg, Austria.
Department of Urology, Hodentumorzentrum, Asklepios Klinik Altona, Hamburg, Germany.
Sci Rep. 2023 Sep 5;13(1):14604. doi: 10.1038/s41598-023-41915-7.
Preoperative homeostasis of sex hormones in testicular germ cell tumor (TGCT) patients is scarcely characterized. We aimed to explore regulation of sex hormones and their implications for histopathological parameters and prognosis in TGCT using a data-driven explorative approach. Pre-surgery serum concentrations of luteinizing hormone (LH), follicle-stimulating hormone (FSH), testosterone (T), estradiol (E2) and prolactin were measured in a retrospective multicenter TGCT cohort (n = 518). Clusters of patients were defined by latent class analysis. Clinical, pathologic and survival parameters were compared between the clusters by statistical hypothesis testing, Random Forest modeling and Peto-Peto test. Cancer tissue expression of sex hormone-related genes was explored in the publicly available TCGA cohort (n = 149). We included 354 patients with pure seminoma and 164 patients with non-seminomatous germ cell tumors (NSGCT), with a median age of 36 years. Three hormonal clusters were defined: 'neutral' (n = 228) with normal sex hormone homeostasis, 'testicle' (n = 91) with elevated T and E2, low pituitary hormones, and finally 'pituitary' subset (n = 103) with increased FSH and LH paralleled by low-to-normal levels of the gonadal hormones. Relapse-free survival in the hormonal subsets was comparable (p = 0.64). Cancer tissue expression of luteinizing hormone- and follicle-stimulating hormone-coding genes was significantly higher in seminomas, while genes of T and E2 biosynthesis enzymes were strongly upregulated in NSGCT. Substantial percentages of TGCT patients are at increased risk of sex hormone dysfunction at primary diagnosis before orchiectomy. TGCT may directly influence systemic hormonal homeostasis by in-situ synthesis of sex hormones.
术前睾丸生殖细胞肿瘤 (TGCT) 患者的性激素内稳态很少被描述。我们旨在通过数据驱动的探索性方法,研究性激素的调节及其对 TGCT 组织病理学参数和预后的影响。在一项回顾性多中心 TGCT 队列(n=518)中,测量了术前血清黄体生成素 (LH)、卵泡刺激素 (FSH)、睾酮 (T)、雌二醇 (E2) 和催乳素的浓度。通过潜在类别分析定义患者群。通过统计假设检验、随机森林模型和 Peto-Peto 检验比较集群之间的临床、病理和生存参数。在公开的 TCGA 队列(n=149)中探索了与性激素相关的基因在癌症组织中的表达。我们纳入了 354 例单纯精原细胞瘤患者和 164 例非精原细胞瘤生殖细胞肿瘤(NSGCT)患者,中位年龄为 36 岁。定义了三个激素群:“中性”(n=228),表现为正常的性激素内稳态;“睾丸”(n=91),表现为 T 和 E2 升高,垂体激素降低;最后是“垂体”亚群(n=103),表现为 FSH 和 LH 增加,同时性腺激素水平低至正常。激素亚群的无复发生存率无差异(p=0.64)。在精原细胞瘤中,黄体生成素和卵泡刺激素编码基因的表达明显升高,而 T 和 E2 生物合成酶的基因则在 NSGCT 中强烈上调。在睾丸切除术之前的原发性诊断中,大量 TGCT 患者存在性激素功能障碍的风险增加。TGCT 可能通过原位合成性激素直接影响全身性激素内稳态。